BiotechTube

VK2809 + Placebos

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NASH - Nonalcoholic Steatohepatitis

Conditions

NASH - Nonalcoholic Steatohepatitis

Trial Timeline

Nov 15, 2019 → Jan 26, 2024

NCT ID
NCT04173065

About VK2809 + Placebos

VK2809 + Placebos is a phase 2 stage product being developed by Viking Therapeutics for NASH - Nonalcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04173065. Target conditions include NASH - Nonalcoholic Steatohepatitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04173065Phase 2Completed

Competing Products

20 competing products in NASH - Nonalcoholic Steatohepatitis

See all competitors
ProductCompanyStageHype Score
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
AZD2693AstraZenecaPhase 1
33
AZD4076 + PlaceboAstraZenecaPhase 1
33
LIK066 + PlaceboNovartisPhase 2
52
Tropifexor (LJN452) + Cenicriviroc (CVC)NovartisPhase 2
52
Tropifexor + LicogliflozinNovartisPhase 2
52
LMB763 + PlaceboNovartisPhase 2
52
Tropifexor (LJN452) + PlaceboNovartisPhase 2
52
TRO19622 + PlaceboRochePhase 2
52
SEL + SIMGilead SciencesPhase 2
51
Seladelpar + PlacebosGilead SciencesPhase 2
51
Placebo + SIMGilead SciencesPhase 2
51
CilofexorGilead SciencesPhase 1
32
Firsocostat + FenofibrateGilead SciencesPhase 1
32
GS-9674 + Placebo to match GS-9674Gilead SciencesPhase 2
51

Other Products from Viking Therapeutics

VK2735Phase 3
72
VK2735Phase 3
72
Placebo + VK2735Phase 2
47
VK2809 + PlaceboPhase 2
47
VK2735 + PlaceboPhase 2
47